warts%20-%20anogenital
WARTS - ANOGENITAL
Anogenital warts (condylomas) are caused by human papillomavirus (HPV) with >90% of the lesions caused by genotypes 6 & 11.
Patients who present with visible warts may also be infected with high-risk HPVs (eg types 16 & 18) which can cause subclinical lesions that are associated with intraepithelial neoplasia, cervical cancer and anogenital cancer.
Many HPV infections are subclinical, transient, and clear spontaneously within 12 months but may also remain latent and reactivate after several years.

Introduction

  • Patient usually presents with lesions in areas that are traumatized by sexual intercourse but may also occur at any site
    • Vagina, cervix, urethral meatus and anal canal
    • Perianal lesions may occur in both sexes but are most common in homosexual men
    • Warts in the anal canal are typically found in penetrative anal sex, though lesions may have developed secondary to collection in this area of genital secretions infected with human papillomavirus (HPV)
    • Extragenital lesions may be seen on the oral cavity, nasal cavity, larynx or conjunctivae

Etiology

  • Anogenital warts (condylomas) are caused by human papillomavirus (HPV) with >90% of the lesions caused by low-risk HPVs genotypes 6 and 11
    • Patients who present with visible warts may also be infected with high-risk HPVs (eg types 16, 18, 31, 33 and 35) which can cause subclinical lesions that are associated with high-grade squamous intraepithelial lesions, cervical cancer and anogenital cancer
    • Many HPV infections are subclinical, transient and clear spontaneously within 12 months but may also remain latent and reactivate after several years

Transmission

  • Most often by sexual contact
    • Risk of acquiring infection increases with multiple sexual partners
    • Direct skin-to-skin contact spreads the infection most efficiently
    • The virus is not transmitted via bodily fluids (eg semen, vaginal discharge) or blood
  • Autoinoculation can occur by scratching, shaving or traumatizing previously infected skin
  • Infection can be passed on even without visible signs of warts 
  • May also be transmitted perinatally (eg from hand warts)

Signs and Symptoms

  • Keratinized and firm on dry hairy skin while nonkeratinized and soft on warm, moist, non-hairy skin
  • Lesion(s) may be singular or more and usually occur as 5 to ≥15 lesions
    • May also be discrete lesions or multiple lesions that may coalesce into confluent plaques
    • Multifocal or multicentric
  • Lesions are often asymptomatic, some may cause little physical discomfort, may be disfiguring and psychologically distressing
  • May be associated with:
    • Pain
    • Pruritus
    • Irritation and soreness (especially around the anus)
    • Distortion of urine flow or bleeding from anus, urethra, or cervix may indicate internal lesions
    • Bleeding and infection if located at site prone to trauma and irritation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.